Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $44.7 million.

  • Haemonetics' Net Income towards Common Stockholders rose 1932.58% to $44.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $175.4 million, marking a year-over-year increase of 3486.37%. This contributed to the annual value of $167.7 million for FY2025, which is 4262.83% up from last year.
  • Per Haemonetics' latest filing, its Net Income towards Common Stockholders stood at $44.7 million for Q4 2025, which was up 1932.58% from $38.7 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Net Income towards Common Stockholders registered a high of $58.0 million during Q1 2025, and its lowest value of -$11.0 million during Q2 2021.
  • Over the past 5 years, Haemonetics' median Net Income towards Common Stockholders value was $32.1 million (recorded in 2022), while the average stood at $27.5 million.
  • In the last 5 years, Haemonetics' Net Income towards Common Stockholders crashed by 16261.2% in 2021 and then surged by 54627.3% in 2022.
  • Haemonetics' Net Income towards Common Stockholders (Quarter) stood at $14.8 million in 2021, then surged by 122.13% to $32.9 million in 2022, then fell by 5.15% to $31.2 million in 2023, then rose by 20.06% to $37.5 million in 2024, then increased by 19.33% to $44.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at $44.7 million for Q4 2025, versus $38.7 million for Q3 2025 and $34.0 million for Q2 2025.